Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclacel Pharmaceuticals, Inc. (UXI4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.4966+0.0018 (+0.36%)
At close: 09:49PM CET
Advertisement
Advertisement
Show:
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

Currency in USD. All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Breakdown
ttm
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
0
0
0
0
0
Operating Expense
27,656
27,656
22,938
10,636
9,682
Operating Income
-27,656
-27,656
-22,938
-10,636
-9,682
Net Non Operating Interest Income Expense
210
210
16
42
224
Other Income Expense
1,531
1,531
188
913
332
Pretax Income
-25,915
-25,915
-22,734
-9,681
-9,126
Tax Provision
-4,717
-4,717
-3,847
-1,236
-1,296
Net Income Common Stockholders
-21,399
-21,399
-19,088
-12,421
-8,031
Diluted NI Available to Com Stockholders
-21,399
-21,399
-19,088
-12,421
-8,031
Basic EPS
-
-1.90
-2.14
-3.42
-9.80
Diluted EPS
-
-1.90
-2.14
-3.42
-9.80
Basic Average Shares
-
11,256
8,926
3,633
816.087
Diluted Average Shares
-
11,256
8,926
3,633
816.087
Total Operating Income as Reported
-27,656
-27,656
-22,938
-10,636
-9,682
Total Expenses
27,656
27,656
22,938
10,636
9,682
Net Income from Continuing & Discontinued Operation
-21,198
-21,198
-18,887
-8,445
-7,830
Normalized Income
-21,389
-21,389
-18,924
-8,464
-7,917
Interest Income
210
210
16
42
224
Net Interest Income
210
210
16
42
224
EBIT
-27,656
-27,656
-22,938
-10,636
-9,682
EBITDA
-27,656
-
-
-
-
Reconciled Depreciation
-
-
43
20
20
Net Income from Continuing Operation Net Minority Interest
-21,198
-21,198
-18,887
-8,445
-7,830
Total Unusual Items Excluding Goodwill
233
233
44
22
101
Total Unusual Items
233
233
44
22
101
Normalized EBITDA
-27,889
-27,889
-22,939
-10,638
-9,763
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
42.4102
42.4102
7.4456
2.8088
14.3432
Advertisement
Advertisement